+44 (0) 20 7549 9987 | USA callers: +1 212 220 8419

Contact Us Now

The Global Drug Delivery Technologies market will reach $259.1bn in 2020 predicts new visiongain report

04 September 2018
Pharma

A new report by visiongain predicts that the Global Drug Delivery Technologies market will reach $259.1bn in 2020. This forecast and others appear in Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes—published in July 2016. Visiongain is a business information provider based in London, UK.

Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes report examines the current and future trends in the growing drug delivery technologies market. As the generic drug industry continues to see rapid growth, big pharma companies will continue to strive for extensions on their product life-cycles. Drug delivery technologies are of high demand not only because of the deep interest shown by pharma companies in recent years but also the dire need to improve patient compliance. Yemi Adebayo, a Pharmaceutical and Medical Devices Analyst at visiongain comments:
“Drug delivery technologies provide ample opportunities for both biopharmaceutical companies that offer services providing new technologies and pharmaceutical companies attempting to extend the product lifecycle of their product. The drug delivery technologies market will see fast growth over the next ten years. The oral drug delivery market remains the most dominant submarket, which is largely due to the convenience of taking drugs orally. However, with increasing numbers of biologic medicines we expect to see the injectable drug delivery tech market grow rapidly over the forecast period. The problem with using the parenteral route for drug delivery is the inconvenience it brings to patients. As such, novel ways of administering biologics will be sought. This, together with the growing burden of an ageing population and rise in chronic diseases in most developed countries will continue to cause demand for new ways of delivering drugs to their intended target.”
In this report, we examine in detail the drug delivery technologies market, and provide analyses and forecasts for regional and national markets. Historical revenues have also been added to strengthen our analysis to demonstrate how this market has changed. Qualitative analysis of the market is given, taking into account governmental policy and regulation, safety, features and more.

Visiongain’s report provides revenue forecasts to 2026 for the global biologics market, the global vaccines market and the global drug delivery technologies market and the leading regional and national drug delivery technologies markets. The report discusses selected leading companies in the market. These companies include Alkermes, 3M, Skyepharma, Becton Dickinson and Company (BD), Antares Pharma, pSivida, Applied Pharma Research (APR), Ethypharm, Glycologic and NanoPass Technologies

Drug Delivery Technologies Market Forecast 2016-2026: Analysis of Oral, Inhalable, Injectable/Implantable, Transdermal, Ocular and Nasal/Buccal Drug Delivery Technologies; Forecasts for Biologics, Vaccines and Major National Markets and Assessment of Leading Drug Delivery Companies including 3M, BD and Alkermes adds to visiongain’s range of analytical reports on industries and markets in healthcare.

For an executive summary please contact:
Email: Sara Peerun on sara.peerun@visiongainglobal.com
Tel: +44 (0) 20 7336 6100

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44 (0) 207 336 61
About visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. From its head office in London, UK, visiongain produces a range of newsletters, business reports and e-zines covering current affairs and market trends in the Energy, Telecoms, Pharmaceutical, Defence, and Materials sectors.
Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional that needs independent, high quality, original analyses to inform their strategic decisions.

Recent News

Visiongain Publishes Cell Therapy Technologies Market Report 2024-2034

The cell therapy technologies market is estimated at US$7,041.3 million in 2024 and is projected to grow at a CAGR of 10.7% during the forecast period 2024-2034.

18 April 2024

Read

Visiongain Publishes Automation in Biopharma Industry Market Report 2024-2034

The global Automation in Biopharma Industry market is estimated at US$1,954.3 million in 2024 and is projected to grow at a CAGR of 7% during the forecast period 2024-2034.

17 April 2024

Read

Visiongain Publishes Anti-obesity Drugs Market Report 2024-2034

The global Anti-obesity Drugs market is estimated at US$11,540.2 million in 2024 and is expected to register a CAGR of 21.2% from 2024 to 2034.

12 April 2024

Read

Visiongain Publishes Inflammatory Bowel Diseases (IBD) Drugs Market Report 2024-2034

The global Inflammatory Bowel Diseases (IBD) Drugs market was valued at US$27.53 billion in 2023 and is projected to grow at a CAGR of 6.2% during the forecast period 2024-2034.

11 April 2024

Read